Abstract:Background: Over the past two decades, the Food and Drug Administration (FDA) has significantly increased the approval of anti−obesity medications (AOMs) for obesity management. Both FDA−approved AOMs (F−AOMs) and off−label AOMs (O−AOMs) have gained popularity and demonstrated promising results in randomized clinical trials (RCTs). However, their effectiveness in real−world settings remains less understood. In this study, we evaluated population−level responses to AOMs and individual variability under real−world conditions, leveraging electronic health records (EHRs) as the primary data source for a comprehensive analysis of obesity relevant metrics. Methods: EHRs of patients with obesity or overweight diagnosis were retrieved from the University of Texas Physician (UT−Physician) and EPIC COSMOS database. F−AOMs and O−AOMs were analyzed for their effects on obesity relevant metrics including body weight, body mass index (BMI), blood pressure (BP), high−density lipoprotein (HDL), low−density lipoprotein (LDL), HbA1c, and triglyceride levels. Results: From the UT−Physician (U) and COSMOS (C) datasets, we identified 444K (2005−2023) and 30M (2018−2023) patients as obese or overweight, respectively. Of these, 72,089 (6.2%) and 10M (~30%) had exposure to AOMs. During the study period, [U:37%; C:48%] of patients underwent more than one treatment session. The median exposure time to F−AOMs are [U:2.9; C:6.1] months. The median exposure time to O−AOMs are [U:2.9; C:14] months. For both cohorts, F−AOMs generally showed superior weight loss effects than O−AOMs. Tirzepatide and semaglutide were the most effective F−AOMs. Tirzepatide achieved 5% and 10% weight loss respectively in [U:65%; C:63%] and [U:33%; C:42%] of patients on long−term [U:76 wks; C:79 wks] exposure. Semaglutide achieved 5% and 10% weight loss respectively in [U:37%; C:45%] and [U:16%; C:25%] of patients on long−term [U:94 wks; C:88 wks] exposure. Both medications also benefited HDL, LDL, triglyceride, and HbA1c levels. Among O−AOMs, metformin demonstrated the most effective long−term [U:143 wks; C:166 wks] results, with [U:27%; C:32%] and [U:9%; C:14%] of patients achieving 5% and 10% weight loss, respectively. Significant individual variability in response was observed across all AOMs, irrespective of diagnosis type or exposure duration. Weight gain was noted in a subset of patients, ranging from [U:15%; C:18%] for tirzepatide (long−term) to [U:59%; C:62%] for lisdexamfetamine (long−term). Significant weight regain was consistently observed in both cohorts after discontinuing phentermine series, zonisamide, topiramate, and lisdexamfetamine. Conclusions: Remarkable differences were observed between real−world evidence from EHR data and RCT reports on AOM effectiveness, highlighting the challenges of applying RCT results to diverse populations in routine practice. The wide variation in individual responses to both FDA−approved and off−label AOMs underscores the importance of personalizing obesity treatment to improve effectiveness, support long−term adherence, and promote sustainable care strategies.

Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022

Pharmacologic management of obesity: Updates on approved medications, indications and risks

Current and future state of pharmacological management of pediatric obesity

Advances in Anti-obesity Pharmacotherapy: Current Treatments, Emerging Therapies, and Challenges

Anti‐Obesity Medication in the Management of Children and Adolescents With Obesity: Recent Developments and Research Gaps

Special considerations for the child with obesity: An Obesity Medicine Association (OMA) clinical practice statement (CPS) 2024

Effectiveness and safety of drugs for obesity

Frequently asked questions to the 2023 obesity medicine association position statement on compounded peptides: A call for action

Current status of anti-obesity medications and performance, an EHR based survey

Nutritional considerations with antiobesity medications

Decoding Obesity Management Medications and the Journey to Informed Treatment Choices for Patients

Worth Their Weight? An Update on New and Emerging Pharmacologic Agents for Obesity and Their Potential Role for Persons with Cardiac Conditions

Obesity medications: A narrative review of current and emerging agents

Artificial intelligence and obesity management: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023

The Science of Obesity Management: An Endocrine Society Scientific Statement

139-OR: An Obesity-centric Approach With and Without Antiobesity Medications Compared with the Usual-Care Approach to Management of Patients with Obesity and Type 2 Diabetes in an Employer Setting—A Pragmatic Randomized Controlled Trial (EMPOWER-T2D)

New insights into the treatment of obesity.

Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience

Medications for Obesity: A Review

Obesity and advocacy: A joint clinical perspective and expert review from the obesity medicine association and the obesity action coalition - 2024

Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review